Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis

被引：30

作者：

Patel, R

Rouse, MS

Piper, KE

Steckelberg, JM

机构：

[1] Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Clin Microbiol, Rochester, MN 55905 USA

[2] Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA

[3] Mayo Clin & Mayo Fdn, Infect Dis Res Lab, Rochester, MN 55905 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2001年 / 45卷 / 02期

关键词：

D O I：

10.1128/AAC.45.2.621-623.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We compared the activities of linezolid (25 mg/kg of body weight, administered intraperitoneally every 8 h) and of vancomycin (25 mg/kg of body weight, administered intraperitoneally every 8 h) in a rat model of vanA vancomycin-resistant Enterococcus faecium experimental endocarditis. Results were expressed as median log(10) CFU per gram of vegetation after 3 days of treatment. The median log(10) CFU per gram of vegetation was 10.1 among 7 untreated control animals, 10.2 among 9 vancomycin-treated animals, and 7.9 among 10 linezolid-treated animals. Linezolid treatment was more active (P < 0.05) than vancomycin treatment or no treatment.

引用

收藏

页码：621 / 623

页数：3

相关论文

共 14 条

[1]

[Anonymous], 1999, METHODS DETERMINING

[2] Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections [J].

Chien, JW ;

Kucia, ML ;

Salata, RA .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :146-151

[3] Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia [J].

Chow, JW ;

Donabedian, SM ;

Zervos, MJ .

CLINICAL INFECTIOUS DISEASES, 1997, 24 (01) :90-91

[4] In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections [J].

Ford, CW ;

Hamel, JC ;

Wilson, DM ;

Moerman, JK ;

Stapert, D ;

Yancey, RJ ;

Hutchinson, DK ;

Barbachyn, MR ;

Brickner, SJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1508-1513

[5] CONTINUOUS INTRAVENOUS VERSUS INTERMITTENT AMPICILLIN THERAPY OF EXPERIMENTAL ENDOCARDITIS CAUSED BY AMINOGLYCOSIDE-RESISTANT ENTEROCOCCI [J].

HELLINGER, WC ;

ROUSE, MS ;

RABADAN, PM ;

HENRY, NK ;

STECKELBERG, JM ;

WILSON, WR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) :1272-1275

[6] Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin:: A synergistic drug combination [J].

Matsumura, S ;

Simor, AE .

CLINICAL INFECTIOUS DISEASES, 1998, 27 (06) :1554-1556

[7] The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium [J].

Moellering, RC ;

Linden, PK ;

Reinhardt, J ;

Blumberg, EA ;

Bompart, F ;

Talbot, GH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :251-261

[8]

National Committee for Clinical Laboratory Standards, 2000, M7A5 NAT COMM CLIN L

[9] In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae [J].

Patel, R ;

Rouse, MS ;

Piper, KE ;

Cockerill, FR ;

Steckelberg, JM .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 30 (02) :89-92

[10] In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae [J].

Patel, R ;

Rouse, MS ;

Piper, KE ;

Steckelberg, JM .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 34 (02) :119-122